natgillin/translations-raw huggingface dataset:
A dry powder aerosol composition for use according to Claim 1 wherein one dosage of the dry powder aerosol composition is divided into two to six unit doses, preferably into three to five unit doses, and most preferably into four unit doses. 
Suhi sastav praškastog aerosola za uporabu prema zahtjevu 1, naznačen time, da je jedna doza suhog sastava praškastog aerosola podijeljena u dvije do šest jediničnih doza, poželjno u tri do pet jediničnih doza, a najbolje u četiri jedinične doze.
A dry powder aerosol composition for use according to Claim 2 wherein the second non-treatment period is from 20 to 36 days, preferably from 26 to 30 days. 
Suhi sastav praškastog aerosola za uporabu prema zahtjevu 2, naznačen time, da je drugi period bez liječenja u trajanju od 20 do 36 dana, poželjno od 26 do 30 dana.
A dry powder aerosol composition for use according to Claim 2 or Claim 6 wherein the first treatment period is from 26 to 30 days, preferably for 28 days. 
Suhi sastav praškastog aerosola za uporabu prema zahtjevu 2 ili zahtjevu 6, naznačen time, da je prvi period liječenja u trajanju od 26 do 30 dana, poželjno traje 28 dana.
A dry powder aerosol composition for use according to Claim 2 wherein the treatment regime of the first treatment period followed by the second non-treatment period is repeated a multiplicity of times. 
Suhi sastav praškastog aerosola za uporabu prema zahtjevu 2, naznačen time, da se režim liječenja ponavlja više puta, kod kojega nakon prvog perioda liječenja slijedi drugi period bez liječenja.
A dry powder aerosol composition for use according to Claim 1 wherein the dry powder aerosol composition comprises particles at least 50% of which have an aerodynamic diameter in the range of from 1 µm to 5 µm. 
Suhi sastav praškastog aerosola za uporabu prema zahtjevu 1, naznačen time, da suhi sastav praškastog aerosola sadrži čestice od kojih najmanje 50% imaju aerodinamični promjer u rasponu od 1 μm do 5 μm.
A dry powder aerosol composition for use according to Claim 1 wherein the powder is prepared by spray-drying. 
Suhi sastav praškastog aerosola za uporabu prema zahtjevu 1, naznačen time, da je prašak pripremljen pomoću sušenja raspršivanjem.
A dry powder aerosol composition for use according to Claim 1, wherein the powder comprises from 40% by weight to 70% by weight of tobramycin. 
Suhi sastav praškastog aerosola za uporabu prema zahtjevu 1, naznačen time, da prašak sadrži od 40 masenih % do 70 masenih % tobramicina.
A dry powder aerosol composition for use according to Claim 13 wherein the powder comprises phospholipid-based spherical particles with porous structures comprising tobramycin, 1,2-distearoyl-sn-glycero-3-phosphocholine and calcium chloride. 
Suhi sastav praškastog aerosola za uporabu prema zahtjevu 13, naznačen time, da prašak sadrži kuglaste čestice na bazi fosfolipida, koje imaju poroznu strukturu sa sadržajem koji obuhvaća tobramicin, 1,2-distearoil-sn-glicero-3-fosfokolin i kalcijev klorid.
A dry powder aerosol composition for use according to any one of the preceding claims wherein the cystic fibrosis patient is suffering from a Pseudomonas aeruginosa endobronchial infection. 
Suhi sastav praškastog aerosola za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time, da pacijent koji boluje od cistične fibroze, pati od endobronhijalne infekcije uzrokovane Pseudomonas aeruginosa.
A dry powder aerosol composition for use according to any one of the preceding claims wherein the dry powder aerosol composition is formulated for administration to the patient using a dry powder inhaler. 
Suhi sastav praškastog aerosola za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time, da se suhi sastav praškastog aerosola formulira za davanje pacijentu uporabom inhalatora za suhi prašak.
A dry powder aerosol composition for use according to Claim 1 wherein the dry powder aerosol composition is disposed either within a single container or within multiple containers within the dry powder inhaler, and the aerosol powder is delivered from the container into the lungs of the cystic fibrosis patient by the inhaler. 
Suhi sastav praškastog aerosola za uporabu prema zahtjevu 1, naznačen time, da se suhi sastav praškastog aerosola raspoređuje unutar jednog spremnika ili unutar više spremnika u inhalatoru za suhi prašak, gdje se praškasti aerosol prenosi pomoću inhalatora iz spremnika u pluća pacijenta koji pati od cistične fibroze.
Tobramycin for use in the treatment of a Pseudomonas aeruginosa endobronchial infection in a cystic fibrosis patient, wherein the tobramycin is in the form of a dry powder aerosol composition comprising from 110 to 115 mg of tobramycin per dosage, the composition is formulated for administration to the endobronchial system of the patient and one dosage of the composition is administered twice a day for a first treatment period of 28 days followed by a second non-treatment period of from 26 to 30 days wherein no tobramycin antibiotic is administered to the endobronchial system of the patient, and then repeating the first and second treatment periods. 
Tobramicin, naznačen time, da se upotrebljava za liječenje endobronhijalne infekcije uzrokovane Pseudomonas aeruginosa kod pacijenta koji pati od cistične fibroze, gdje je tobramicin u obliku suhog sastava praškastog aerosola koji sadrži od 110 do 115 mg tobramicina po jednoj dozi, pri čemu se sastav formulira za primjenu u endobronhijalni sustav pacijenta, kada se jedna doza sastava daje dva puta dnevno za vrijeme prvog perioda liječenja u trajanju od 28 dana, zatim slijedi drugi period bez liječenja u trajanju od 26 do 30 dana, kada se antibiotik tobramicin ne daje u endobronhijalni sustav pacijenta, te se nakon toga ponavljaju prvi i drugi period liječenja.
Tobramycin for use according to Claim 18 wherein one dosage of the dry powder aerosol composition comprising from 110 to 115 mg of tobramycin is divided into three to five unit doses, preferably into four unit doses. 
Tobramicin za uporabu prema zahtjevu 18, naznačen time, da je jedna doza suhog sastava praškastog aerosola, koja sadrži od 110 do 115 mg tobramicina, podijeljena u tri do pet jediničnih doza, poželjno u četiri jedinične doze.
A compound represented by the structural formula or a tautomer, pharmaceutically acceptable salt, solvate or clathrate thereof, wherein: ring A is an aryl or a heteroaryl, wherein the aryl or the heteroaryl are optionally further substituted with one or more substituents in addition to R3; 
Spoj prikazan slijedećom strukturnom formulom: [image] ili njegov tautomer, farmaceutski prihvatljiva sol, solvat ili klatrat, pri čemu je prsten A aril ili heteroaril, pri čemu su aril ili heteroaril opcijskijoš supstituirani sa jednim ili više supstituenata pored R3;
The compound of Claim 1 represented by the following structural formula: or a tautomer, pharmaceutically acceptable salt, solvate or clathrate thereof, wherein 
Spoj prema zahtjevu 1, pri čemu je spoj prikazan slijedećom strukturnom formulom [image] ili njegov tautomer, farmaceutski prihvatljiva sol, solvat ili klatrat, pri čemu
The compound of Claim 1 represented by one of the following structural formulas: or a tautomer, pharmaceutically acceptable salt, solvate or clathrate thereof, wherein 
Spoj prema zahtjevu 1, pri čemu je spoj prikazan jednom od slijedećih strukturnih formula: [image] ili njegov tautomer, farmaceutski prihvatljiva sol, solvat ili klatrat, pri čemu:
treating or preventing a proliferation disorder in a mammal; 
liječenje ili sprječavanje proliferativnog poremećaja kod sisavaca;
inducing degradation of a c-kit protein; 
izazivanje degradacije c-kit proteina;
treating a c-kit associated cancer in a mammal; 
tretiranje c-kita u vezi sa rakom kod sisavaca;
Hydroalcoholic gel pharmaceutical composition comprising: 
Farmaceutska smjesa u obliku hidroalkoholnog gela koja sadrži:
about 60 % to about 80 % (w/w) of an alcohol selected from the group consisting of ethanol and isopropanol; 
od 60% do 80% (w/w) alkohola izabranog iz grupe koja obuhvaća etanol i izopropanol;
a sufficient amount of a thickening agent to give the composition a viscosity in excess of about 9000 cps; and 
dovoljnu količinu sredstva za zgušnjavanje koje će dati smjesi viskoznost u suvišku od 9000 cps; i vodu.
the P1 deprotection step is carried out in the presence of a solvent which is acetic acid or a mixture of acetic acid with an alcohol or with an ester. 
faza skidanja zaštite P1 provodi se u prisutnosti otapala koje je octena kiselina ili smjesa octene kiseline i alkohola ili estera.
A process according to any one of the preceding claims, for preparing the heminapadisylate or mesylate salt of the compound of formula (I). 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da se njime priprema heminapadisilatna ili mesilatna sol spoja formule (I).
A process according to claim 11, wherein the amount of the catalyst used is less than 5%. 
Postupak u skladu s patentnim zahtjevom 10, naznačen time, da korištena količina katalizatora iznosi manje od 5 %.
A process according to claim 13, wherein the solvent is methanol/acetic acid (1:1) 
Postupak u skladu s patentnim zahtjevom 12, naznačen time, da je otapalo metanol/octena kiselina (1:1).
Compound according to claim 1 selected from the group consisting of 
Spoj prema zahtjevu 1, naznačen time da je odabran iz skupine koja sadrži
Method for the preparation of a compound according to one of the claims 1 to 7, characterized in that 
Postupak za dobivanje spoja prema jednom od zahtjeva 1 do 7, naznačen time da
by introducing an alkyl group, or 
sa uvođenjem alkilne skupine, ili
a compound of formula I is isolated and/or treated with an acid or a base, to obtain the salt thereof. 
spoj sa formulom I je izoliran i/ili obrađen sa kiselinom ili bazom, da se dobije njegova sol.
A compound according to one of the claims 1 to 7 for use as 11β-HSD1 inhibitor. 
Spoj prema jednom od zahtjeva 1 do 7 naznačen time da je za uporabu kao inhibitor 11β-HSD1.
Use of a compound according to one of the claims 1 to 7 for the preparation of a medicament. 
Uporaba spoja prema jednom od zahtjeva 1 do 7 naznačena time da je za dobivanje lijeka.
Use of a compound according to one of the claims 1 to 7 for the preparation of a medicament for the treatment and/or prevention of one ore more disease or condition selected from the group consisting of metabolic syndrome, diabetes, especially non-insulin dependent diabetes mellitus, prediabetes, insulin resistance, low glucose tolerance, hyperglycemia, obesity and weight-related disorders, lipid disorders such as dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL levels or high LDL levels, glaucoma, osteoporosis, glucocorticoid-mediated effects on neuronal function, such as cognitive impairment, anxiety or depression, neurodegenerative disease, immune disorders such as tuberculosis, leprosy or psoriasis, hypertension, atherosclerosis and its sequelae, vascular restenosis, cardiovascular diseases, pancreatitis, retinopathy, neuropathy and nephropathy. 
Uporaba spoja prema jednom od zahtjeva 1 do 7 naznačena time da je za dobivanje lijeka za liječenje i/ili sprečavanje jedne ili više bolesti ili stanja koje su odabrane iz skupine koja sadrži metabolički sindrom, dijabetes, posebice dijabetes melitus koji nije ovisan o inzulin, pred-dijabetes, inzulinsku rezistenciju, nisku toleranciju glukoze, hiperglikemiju, pretilost i poremećaje povezane sa težinom, lipidne poremećaje, kao što su dislipidemija, hiperlipidemija, hipertrigliceridemija, hiperkolesterolemija, niska razina HDL ili visoka razina LDL, glaukom, osteoporozu, glukokortikoidno-posredovane učinke na neuronsku funkciju, kao što je kognitivno oštećenje, anksioznost ili depresija, neurodegenerativne bolesti, imunološke poremećaje poput tuberkuloze, gube ili psorijaze, hipertenziju, aterosklerozu i njihove posljedice, restenozu, kardiovaskularne bolesti, pankreatitis, retinopatiju, neuropatiju i nefropatiju.
Composition according to claim 3 characterized in that said polar phospholipids have a greater than 97% degree of acetone insolubility. 
Smjesa prema zahtjevu 4 naznačena time što polarni fosfolipidi imaju stupanj netopljivosti u acetonu veći od 97%.
Composition according to claim 1 characterized by containing said active principle and phospholipids in a weight ratio from about 1:0.1 to about 1:20. 
Smjesa prema zahtjevu 1 naznačena time što su sukralfat i fosfolipidi sadržani u masenom omjeru od oko 1:0.1 do oko 1:20.
Use according to claim 13 characterized in that said phospholipids have a greater than 97% degree of acetone insolubility. 
Uporaba prema zahtjevu 15 naznačena time što polarni fosfolipidi imaju stupanj netopljivosti u acetonu veći od 97%.
is the width of the cylindrical core (5) measured according to the X direction at the extremity (54) of the first part (51); 
je širina cilindrične jezgre (5) izmjerena prema smjeru X na završetku (54) prvog dijela (51);
A is the area of the cross section of the cylindrical core (5) in the plane (Y, Z). 
A je područje presjeka cilindrične jezgre (5) u ravnini (Y, Z).
The facing element according to preceding claim wherein the second part (52) has a continuously decreasing size from the virtual straight line (53) to the extremity (55) directed to the rear face (32). 
Element obloge u skladu s prethodnim patentnim zahtjevom pri čemu drugi dio (52) ima neprekidno padajuću veličinu od prividne ravne linije (53) do završetka (55) usmjerenog prema stražnjoj strani (32).
is the largest distance between the rear face (32) and the front face (31) measured according to a line passing through the cylindrical core (5) along the Y direction. 
najveća udaljenost između stražnje strane (32) i prednje strane (31) izmjerena prema liniji koja prolazi kroz cilindričnu jezgru (5) duž smjera Y.
The facing element according to any of preceding claims wherein the second part (52) of the cylindrical core cross section is chosen in the list consisting of half-circle, half-ellipse, half-oval, triangle, trapezoid quadrilateral, rectangle. 
Element obloge u skladu s bilo kojim od prethodnih patentnih zahtjeva pri čemu je drugi dio (52) cilindričnog presjeka odabran iz liste koja se sastoji od polukruga, poluelipse, poluovala, trokuta, kvadrilateralnog trapezoida, pravokutnika.
The stabilized soil structure of any of claims 10 to 12 wherein the two segments (26, 27) extending the open strip loop (25) come out of the facing through a same slot (36). 
Stabilizirana struktura tla iz bilo kojeg od patentnih zahtjeva 10 do 12 pri čemu dva dijela (26, 27) koja produžuju otvorenu omču vrpce (25) izlaze van obloge kroz isti otvor (36).
The stabilized soil structure of any of claims 10 to 12 wherein the two segments (26, 27) extending the open strip loop (25) come out of the facing through two different slots (121, 122). 
Stabilizirana struktura tla iz bilo kojeg od patentnih zahtjeva 10 do 12 pri čemu dva dijela (26, 27) koja produžuju otvorenu omču vrpce (25) izlaze van obloge kroz različite otvore (121, 122).
from 0 to 6% by weight of an inorganic carbonate, and veterinarily acceptable adjuvants and/or excipients, as an anti-inflammatory and/or antimicrobial agent for use in the prevention and treatment of foot diseases in ungulates. 
od 0 do 6 težinskih % neorganskog karbonata, i veterinarski prihvatljive adjuvante i/ili inertne punitelje, kao anti-inflamatorno i/ili antimikrobialno sredstvo za uporabu u prevenciji i liječenju bolesti stopala kod papkara i kopitara.
The composition for use of claim 1, wherein said foot diseases are white line disease, digital dermatitis (Mortellaro Disease), interdigital dermatitis, solar ulcers, white line diathesis, laminitis, sole abscesses and interdigital phlegmon. 
Kompozicija za uporabu prema patentnom zahtjevu 1, naznačena time što su navedene bolesti stopala bolesti bijele linije, digitalni dermatitis (Mortellaro bolest), interdigitalni dermatitis, solarni ulceri, dijateza bijele linije, laminitis, apscesi tabana i interdigitalne flegmone.
The composition for use of claim 1 or 2, wherein said powder composition further comprises a powder dyeing agent. 
Kompozicija za uporabu prema patentnom zahtjevu 1 ili 2, naznačena time što navedena kompozicija u obliku praška dalje sadrži sredstvo za bojenje praška.
The composition for use of claim 4, wherein said powder composition is dissolved in an aqueous medium until a concentration of at least 250 ppm of chlorine is obtained. 
Kompozicija za uporabu prema patentnom zahtjevu 4, naznačena time što je navedena kompozicija u obliku praška otapana u vodenom mediju sve dok nije dobijena koncentracija od najmanje 250 ppm klora.
The composition for use of any one of claims 1-5, wherein said powder composition consists of: 
Kompozicija za uporabu prema bilo kojem od patentnih zahtjeva 1-5, naznačena time što se navedena kompozicija u obliku praška sastoji od:
The composition for use of claim 6, wherein said powder composition consists of: 
Kompozicija za uporabu prema patentnom zahtjevu 6, naznačena time što se navedena kompozicija u obliku praška sastoji od:
A process for the preparation of Compound I of the formula comprising the steps of 
Postupak pripreme Spoja I formule [image] koji obuhvaća korake
reacting Compound A of the formula with a methylating agent in a suitable solvent to afford Compound B of the formula 
reakcije Spoja A formule [image] Spoj A sa sredstvom za metiliranje u odgovarajućem otapalu radi dobivanja Spoja B formule [image] Spoj B
which is reacted in a continuous oxidation followed by a quench reaction to prepare Compound C of the formula and protecting to convert Compound C to Compound D of the formula 
koji reagira u kontinuiranoj oksidaciji nakon čega slijedi reakcija gašenja radi pripreme Spoja C formule [image] Spoj C i zaštita da se Spoj C prevede u Spoj D formule [image] Spoj D
chlorinating Compound D to afford Compound E of the formula 
kloriranje Spoja D radi dobivanja Spoja E formule [image] Spoj E
which is reacted with a Cbz-L-alanine and a coupling agent to afford Compound J of the formula 
koji reagira s Cbz-L-alaninom i sredstvom za spajanje radi dobivanja Spoja J formule [image] Spoj J
which is deprotected and crystallized to afford crystalline Compound I. A continuous reaction process for the preparation Compound C of the formula from Compound B of the formula comprising oxidation of Compound B in a continuous reactor through which a solution of Compound B and hydrogen peroxide and an acid, while being cooled, are contacted as they continuously flow through the reactor. 
Postupak kontinuirane reakcije za pripremu Spoja C formule [image] Spoj C iz Spoja B formule [image] Spoj B koji obuhvaća oksidaciju Spoja B u kontinuiranom reaktoru kroz koji u doticaj dolaze otopina Spoja B i vodikov peroksid i kiselina, dok se istodobno hlade, i dok kontinuirano prolaze kroz reaktor.
The process according to Claim 2 wherein Compound C, which is not isolated, is protected with pivaloyl chloride and a base to afford Compound D. 
Postupak prema zahtjevu 2 gdje se Spoj C, koji nije izoliran, zaštićuje pivaloil kloridom i bazom radi dobivanja Spoja D.
The process according to Claim 2 wherein the continuous reaction process involves running the reaction through a low temperature zone and a high temperature zone strictly controlled to avoid thermal runaway. 
Postupak prema zahtjevu 2 gdje kontinuirani reakcijski postupak obuhvaća protok reakcije kroz zonu niske temperature i zonu visoke temperature pod strogom kontrolom da bi se izbjegao gubitak topline.
The process according to Claim 4 wherein the temperature of the reactants in the high temperature zone is kept in a range of about 12-18°C. 
Postupak prema zahtjevu 4 gdje gdje se temperatura reaktanata u zoni visoke temperature održava u rasponu od oko 12-18°C.
The process according to Claim 11 wherein the coupling agent is EDAC-HCl. 
Postupak prema zahtjevu 11 gdje je sredstvo za vezanje EDAC-HCl.
The process according to Claim 1 wherein in step e) NaOMe in acetonitrile and (R)-(+)-propylene oxide in water, is used to afford Compound H. 
Postupak prema zahtjevu 1 gdje se u koraku e) NaOMe u acetonitrilu i (R)-(+)-propilen oksid u vodi koriste za dobivanje Spoja H.
A use of a pyrazolo pyridine derivative according to Formula (I), wherein G1, G2, G3, G4 and G5 are as defined in any one of the preceding claims, as well as pharmaceutically acceptable salts thereof, for the preparation of a pharmaceutical composition for the treatment or prophylaxis of a disease or condition selected from cardiovascular disorders, respiratory disorders, metabolism disorders, skin disorders, bone disorders, neuroinflammatory and/or neurodegenerative disorders, kidney diseases, reproduction disorders, diseases affecting the eye and/or the lens and/or conditions affecting the inner ear, inflammatory disorders, liver diseases, pain, cancers, allergic disorders, traumatisms, septic, hemorrhagic and anaphylactic shock, and diseases or disorders of the gastrointestinal system. 
Upotreba derivata pirazolo piridina formule (I), naznačena time da su G1, G2, G3, G4 i G5 definirani u bilo kojem od prethodnih patentnih zahtjeva, kao i njegovih farmaceutski prihvatljivih soli, za pripremu farmaceutskog sastava za liječenje ili profilaksu bolesti ili stanja odabranih od kardiovaskularnih poremećaja, respiratornih poremećaja, poremećaja metabolizma, poremećaja na koži, poremećaja kostiju, neuroinflamatornih i/ili neurodegenerativnih poremećaja, bolesti bubrega, reproduktivnih poremećaja, bolesti oka i/ili očne leće i/ili stanja koja utječu na unutarnje uho, inflamatornih poremećaja, oboljenja jetre, boli, raka, alergijskih oboljenja, traume, septičkog, hemoragijskog i anafilaktičkog šoka i bolesti ili poremećaja gastrointestinalnog sustava.
A compound according to claim 1, wherein A represents wherein the asterisks indicate the bond that is linked to the pyridine group of Formula (I); and a salt of such a compound. 
Spoj prema zahtjevu 1, naznačen time, da A predstavlja [image] gdje zvjezdice označavaju vezu koja je spojena na piridin-skupinu formula (I); i sol takvog spoja.
and a salt of such a compound. 
i sol takvog spoja.
A pharmaceutical composition comprising a compound according to any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj prema bilo kojem od zahtjeva 1 do 17, ili njegovu farmaceutski prihvatljivu sol i farmaceutski prihvatljiv nosač.
represents either R3 represents a hydrogen atom or a C1-C3 alkyl group; 
predstavlja ili [image] predstavlja atom vodika ili C1-C3 alkilnu skupinu;
a group in which m is 1 or 2, q is 0, 1 or 2 and each R independently represents a halogen atom or a hydroxyl, methyl, cyano, trifluoromethyl, S(O)h-methyl or methoxy group; 
skupinu [image] gdje m je 1 ili 2, q je 0, 1 ili 2 i svaki R neovisno predstavlja atom halogena ili hidroksilnu, metilnu, cijano, trifluorometilnu, S(O)h-metilnu ili metoksi skupinu;
represents an oxygen or sulphur atom or a group NH or CH2; 
predstavlja atom kisika ili sumpora ili skupinu NH ili CH2;
A pharmaceutical composition according to claim 21, which is a heptafluoroalkane aerosol suitable for administration by oral or nasal inhalation. 
Farmaceutski pripravak prema zahtjevu 21, naznačen time da je u obliku heptafluoroalkanskog aerosola pogodnog za davanje oralnim putem ili nazalnu inhalaciju.
A pharmaceutical composition according to claim 21, which is a dry powder formulation suitable for administration by oral or nasal inhalation. 
Farmaceutski pripravak prema zahtjevu 21, naznačen time da je formulacija suhog praha pogodna za davanje oralnim putem ili nazalnu inhalaciju.